Genomic annotation and pathway analysis

CC C. Christiansen
JC J. E. Castillo-Fernandez
AD A. Domingo-Relloso
WZ W. Zhao
JM J. S. El-Sayed Moustafa
PT P.-C. Tsai
JM J. Maddock
KH K. Haack
SC S. A. Cole
SK S. L. R. Kardia
MM M. Molokhia
MS M. Suderman
CP C. Power
CR C. Relton
AW A. Wong
DK D. Kuh
AG A. Goodman
KS K. S. Small
JS J. A. Smith
MT M. Tellez-Plaza
AN A. Navas-Acien
GP G. B. Ploubidis
RH R. Hardy
JB J. T. Bell
ask Ask a question
Favorite

Genomic annotation of smoking-DMPs was carried out initially using the EPIC Illumina manifest, for the purpose of identifying novel CpG-sites that are specific to the EPIC-array, for allocating CpG-sites to genes, and relative to CpG-density, including CpG island (CGI), CGI-shore, CGI-shelf, and open sea. Further genomic annotations took into account data from the ENCODE project [20]. We explored if smoking-DMPs mapped within ChromHMM [11] categories to assess enrichment or depletion in smoking-DMPs relative to different functional genomic domains, including insulators, enhancers and specific transcription factors binding sites. In the enrichment analysis, we considered all smoking-DMP probes mapping to a specific annotation category compared to the total number of probes tested that mapped to that category. For each genome annotation category, the results show the log fold change for smoking-DMP probes compared to total probes tested, and the significance of the difference is based on a Fisher’s exact test. Pathway analysis was carried out for genes annotated to smoking-DMPs using Ingenuity Pathway Analysis (IPA; QIAGEN Inc. https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A